Pfizer is Backing This Micro-cap Stock

                                                                                                                                                                                                                                                                                                                                                                                                                December 22, 2022 | [Read Online]( Pfizer is Backing This Micro-cap Stock Sponsored by Good day, 360 – Here are our top 3 trade ideas today – these setups look primed! And a special invitation to join [HERE]( for a 1pm ETexplosive penny stock trading session with Jason Bond in Lightning Alerts⚡. Learn the exact steps he used to spot AMAM at $.56 before it shot up 1000% the same day! And at 7pm ET he’ll be doubling down [HERE]( on his top 3 catalysts for swing trading penny stocks – don’t miss it ORIC - Over 50% higher in pre-market after reporting a clinical development collaboration with Pfizer and $25 million equity investment from Pfizer ENPH - Piper Sandler maintains overweight on Enphase Energy, raises price target to $350 GROM - Low float up over 40% on no news A Message from RYSE* Hottest Sector? Arguably Home Tech. Investors? Could be You. Want to invest in the next big brand name in your home and get in on the ground floor of an innovative technology company? Meet [RYSE]( - the first retrofit solution to motorize and automate installed window blinds and shades, all controlled by a smartphone app. And it’s no surprise that RYSE has attracted top investors. Here’s why they like it: - Incredible historical returns: early investors have seen their shares 10x - $5 million in lifetime revenues with over 35,000 units sold. - 5 defensible patents lock in RYSE position in the growing market - SmartShade market is growing 55% annually with a $158 billion TAM Even better, smart home technologies are getting bid up in the private markets – Google acquired Nest for $3.2 billion and Amazon acquired Ring for $1.2 billion. RYSE is seeking investors to fuel the next phase of growth. Contracts with big box retailers and agreements in place with large commercial real estate developers, landlords, hotels and offices. [Learn more about becoming a shareholder in this innovative startup!]( *This is an issuer-paid advertisement, see disclosure below ORIC - Over 50% higher in pre-market after reporting a clinical development collaboration with Pfizer and $25 million equity investment from Pfizer ORIC Pharmaceuticals reported it would collaborate with Pfizer for ORIC-533 in Multiple Myeloma. It would also offer 5.38 million shares of common stock directly to Pfizer at $4.65/share. That represents a premium of over 50% to the last closing price of $3 for ORIC. $4.65/sh is the purchase price from Pfizer and this may be an important pivot point today. Above it, there is potential resistance at $5 and the $5.50 area. Below $4.65 there is potential support at $4.40 and then $4.10. $4 is an important psychological level and there is a gap to fill to $3 below that. ENPH - Piper Sandler maintains overweight on Enphase Energy, raises price target to $350 ENPH has been one of the hottest stocks in the hottest sector this year. The Solar energy company’s stock is up over 150% this year, and despite the recent market pullback it is still only around 6-7% off all-time highs. It has been consolidating at these levels for quite a while so this price target increase could be the catalyst to send it higher. $315 was prior support and could be an important pivot level. Above it, targets to the upside are $320, $325, $330 and then all-time highs around $340. Below $315, there is potential support at $310, $304 and then the psychologically important $300 level. GROM - Low float up over 40% on no news Grom Social Enterprises is a low float stock with less than 2 million shares in the float according to Finviz. The company had a 1 for 30 reverse split on Dec 9th, 2022. It’s been trading in a tight consolidation since the reverse split and perhaps someone has been accumulating the stock over the past couple of weeks. $1.91-$1.94 was a support area in the pre-market. Above it there is a major resistance level at the $2.30 area which is the pre-market high. Above that there is a gap to fill at $3.86 with potential resistance at $3 which was prior support. Below $1.91 there is potential support at $1.70 and below that there is a gap to fill at yesterday’s close of $1.51. Economic Calendar Thursday GDP 8:30am ET Jobless Claims 8:30am ET Chicago Fed Activity Index 8:30am ET Corporate Profits 8:30am ET Leading Indicators 10:00am ET EIA Natural Gas Report 10:30am ET KC Fed Mfg Index 11:00am ET Earnings for Thursday After Market: AVO, LMNR META GOOG Tech Giants Ditch Office Space In London And Europe – FT TSLA Tesla Sends Shanghai Boss and Aides to Jumpstart US Output [Reuters]( COSM Successful Closing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market GD General Dynamics Electric Boat Awarded $5.1 Billion by U.S. Navy for Columbia-Class Submarines MRNA Moderna Finalizes Strategic Partnership with UK Government [Yahoo]( MRK Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer TSN Hundreds of Tyson Foods Staff Leaving the Company, Including Senior Managers [WSJ]( BBIO: BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 KMX Carmax Pauses Share Buyback After Quarterly Profit Plunges 86% [Nasdaq.com]( VORB: Virgin Orbit Receives U.K.’s First Orbital Launch License; All LauncherOne Systems Green for Upcoming Mission INMB: INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease GOOG GOOGL stock target slashed at Needham on a weaker ad spending outlook in 2023 RIGL Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation COMS: COMSovereign Announces the Sale of Its Sky Sapience Drone Subsidiary To Your Success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) thirty thousand dollars in cash and thirty thousand in shares to run advertisements enhancing public awareness of the company. Raging Bull is currently invested in this company. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements.In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 lee, NH 03861, United States [Publish on beehiiv](